Tianjin Medical University Cancer Institute and Hospital: Lymphoma trials

The registry lists 15 Lymphoma studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 12 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 10Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT AssessmentNot yet recruitingNCT07206264Phase 2
• A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FLNot yet recruitingNCT07031700Phase 2
• BR Combined With OR in Treatment-naïve Marginal Zone LymphomaNot yet recruitingNCT07008053Phase 2
• A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesRecruitingNCT06914037Phase 1
• Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular LymphomaRecruitingNCT06704555Phase 2
• Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular LymphomaNot yet recruitingNCT06474481Phase 2
• CMOEP in the Treatment of Untreated Peripheral T-cell LymphomaRecruitingNCT06433362Phase 2
• Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06395870Phase 1
• A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete RemissionNot yet recruitingNCT05874778Phase 2
• Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's LymphomaEnrolling by invitationNCT05683704Phase 2
• AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFHEnrolling by invitationNCT05678933Phase 3
• CMOEP in the Treatment of Untreated Peripheral T-cell LymphomaNot yet recruitingNCT05458180Phase 1
• A Study of OLR in First-line Treatment of Mantle Cell LymphomaStatus unknownNCT05076097Phase 2
• A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedNCT04696432Phase 1
• Trial of Endostar Combined With CHOPT for T Cell LymphomaStatus unknownNCT01430013Phase 2